Integrating BRAF/MEK inhibitors into combination therapy for melanoma
Open accessThe DOI matches its Crossref record; 3 of the 3 references it cites were found in a registry or an index.
Abstract
The discovery of BRAF mutations in melanoma has not yet translated into clinical success, suggesting that BRAF/MEK inhibitors will need to be combined with other agents. In the current review, we discuss other pathways likely to be important for melanoma progression and suggest possible drug combinations for future clinical testing.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Melanoma biology and new targeted therapy
Gray-Schopfer, V., Wellbrock, C., & Marais, R. (2007) · Nature · doi:10.1038/nature05661 · Cited by 1,371 · cited 5×
“In vitro studies have shown that BRAF V600E is an oncogene in immortalised mouse melanocytes (Gray-Schopfer et al, 2007), and the selective downregulation of BRAF V600E using RNAi causes cell death and reversal of the melanoma phenotype (Hingorani et al, 2003).”
BackgroundInfluentialmTOR Is Activated in the Majority of Malignant Melanomas
Karbowniczek, M., Spittle, C. S., Morrison, T., Wu, H., & Henske, E. P. (2008) · Journal of Investigative Dermatology · doi:10.1038/sj.jid.5701074 · Cited by 168 · cited 2×
“There is evidence that PLX-4032 and its tool-compound counterpart PLX-4720 induces some limited apoptosis in melanoma cell lines with the V600E mutation but not in those that are BRAF wild type (Tsai et al, 2008).”
BackgroundVerhaegen, M., Bauer, J. A., Martín de la Vega, C., Wang, G., Wolter, K. G., Brenner, J. C., Nikolovska-Coleska, Z., Bengtson, A., Nair, R., Elder, J. T., et al. (2006) · Cancer Research · doi:10.1158/0008-5472.can-06-1748 · Cited by 140 · cited 1×
“…18 December 2008; published online 20 January 2009 *Correspondence: Dr KSM Smalley; E-mail: Keiran.Smalley@Moffitt.org British Journal of Cancer (2009) 100, 431 – 435 & 2009 Cancer Research UK All rights reserved 0007 – 0920/09 $32.00 www.bjcancer.com or Mcl-1 expression (Verhaegen et al, 2006).”
BackgroundInfluential
Cited by
Frederick, D. T., Piris, A., Cogdill, A. P., Cooper, Z. A., Lezcano, C., Ferrone, C. R., Mitra, D., Boni, A., Newton, L. P., Liu, C., et al. (2013) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-12-1630 · Cited by 944
Targeting the RAS/RAF/MAPK pathway for cancer therapy: from mechanism to clinical studies
Bahar, M. E., Kim, H. J., & Kim, D. R. (2023) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-023-01705-z · Cited by 888
Boni, A., Cogdill, A. P., Dang, P., Udayakumar, D., Njauw, C.-N. J., Sloss, C. M., Ferrone, C. R., Flaherty, K. T., Lawrence, D. P., Fisher, D. E., et al. (2010) · Cancer Research · doi:10.1158/0008-5472.can-10-0118 · Cited by 742
“To address these issues, combination of BRAF/MAPK-targeted therapy with other signal transduction inhibitors or with conventional chemotherapy has been proposed (9).”
BackgroundSelf-citationChappell, W. H., Steelman, L. S., Long, J. M., Kempf, R. C., Abrams, S. L., Franklin, R. A., Bäsecke, J., Stivala, F., Donia, M., Fagone, P., et al. (2011) · Oncotarget · doi:10.18632/oncotarget.240 · Cited by 510
Melanoma: from mutations to medicine
Tsao, H., Chin, L., Garraway, L. A., & Fisher, D. E. (2012) · Genes & Development · doi:10.1101/gad.191999.112 · Cited by 496
“There are several other BRAF inhibitors that are currently undergoing clinical testing (Smalley and Flaherty 2009).”
Metadata
- Authors
- Smalley, K. S. M., & Flaherty, K. T.
- Venue
- British Journal of Cancer
- Published
- 2009-01-20
- Volume
- 100
- Issue
- 3
- Pages
- 431-435
- ISSN
- 0007-0920 (ISSN-L)
- 1532-1827
- OpenAlex
- W1972726145
- Cited by
- 89
- References
- 3
- FWCI
- 6.12
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.